Conclusions
HDM-SLIT-tablet is a safe and well-tolerated AR treatment. AEs occur often but are mostly mild and decreasing during the first year. CARAT scores improved and symptomatic medication use decreased suggesting better control of AR with HDMSLIT-tablet treatment. Compliance, tolerability, and treatment satisfaction are good. However, patient follow-up and compliance remain important points of attention when starting HDM SLIT-tablet.
Keywords: Allergic Rhinitis, Control of Allergic Rhinitis and Asthma Test (CARAT), House dust mite (HDM), Safety, Sublingual immunotherapy tablet